Cargando…

M2e-based universal influenza vaccines: a historical overview and new approaches to development

The influenza A virus was isolated for the first time in 1931, and the first attempts to develop a vaccine against the virus began soon afterwards. In addition to causing seasonal epidemics, influenza viruses can cause pandemics at random intervals, which are very hard to predict. Vaccination is the...

Descripción completa

Detalles Bibliográficos
Autores principales: Mezhenskaya, Daria, Isakova-Sivak, Irina, Rudenko, Larisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800501/
https://www.ncbi.nlm.nih.gov/pubmed/31629405
http://dx.doi.org/10.1186/s12929-019-0572-3
_version_ 1783460457457123328
author Mezhenskaya, Daria
Isakova-Sivak, Irina
Rudenko, Larisa
author_facet Mezhenskaya, Daria
Isakova-Sivak, Irina
Rudenko, Larisa
author_sort Mezhenskaya, Daria
collection PubMed
description The influenza A virus was isolated for the first time in 1931, and the first attempts to develop a vaccine against the virus began soon afterwards. In addition to causing seasonal epidemics, influenza viruses can cause pandemics at random intervals, which are very hard to predict. Vaccination is the most effective way of preventing the spread of influenza infection. However, seasonal vaccination is ineffective against pandemic influenza viruses because of antigenic differences, and it takes approximately six months from isolation of a new virus to develop an effective vaccine. One of the possible ways to fight the emergence of pandemics may be by using a new type of vaccine, with a long and broad spectrum of action. The extracellular domain of the M2 protein (M2e) of influenza A virus is a conservative region, and an attractive target for a universal influenza vaccine. This review gives a historical overview of the study of M2 protein, and summarizes the latest developments in the preparation of M2e-based universal influenza vaccines.
format Online
Article
Text
id pubmed-6800501
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68005012019-10-22 M2e-based universal influenza vaccines: a historical overview and new approaches to development Mezhenskaya, Daria Isakova-Sivak, Irina Rudenko, Larisa J Biomed Sci Review The influenza A virus was isolated for the first time in 1931, and the first attempts to develop a vaccine against the virus began soon afterwards. In addition to causing seasonal epidemics, influenza viruses can cause pandemics at random intervals, which are very hard to predict. Vaccination is the most effective way of preventing the spread of influenza infection. However, seasonal vaccination is ineffective against pandemic influenza viruses because of antigenic differences, and it takes approximately six months from isolation of a new virus to develop an effective vaccine. One of the possible ways to fight the emergence of pandemics may be by using a new type of vaccine, with a long and broad spectrum of action. The extracellular domain of the M2 protein (M2e) of influenza A virus is a conservative region, and an attractive target for a universal influenza vaccine. This review gives a historical overview of the study of M2 protein, and summarizes the latest developments in the preparation of M2e-based universal influenza vaccines. BioMed Central 2019-10-19 /pmc/articles/PMC6800501/ /pubmed/31629405 http://dx.doi.org/10.1186/s12929-019-0572-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Mezhenskaya, Daria
Isakova-Sivak, Irina
Rudenko, Larisa
M2e-based universal influenza vaccines: a historical overview and new approaches to development
title M2e-based universal influenza vaccines: a historical overview and new approaches to development
title_full M2e-based universal influenza vaccines: a historical overview and new approaches to development
title_fullStr M2e-based universal influenza vaccines: a historical overview and new approaches to development
title_full_unstemmed M2e-based universal influenza vaccines: a historical overview and new approaches to development
title_short M2e-based universal influenza vaccines: a historical overview and new approaches to development
title_sort m2e-based universal influenza vaccines: a historical overview and new approaches to development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800501/
https://www.ncbi.nlm.nih.gov/pubmed/31629405
http://dx.doi.org/10.1186/s12929-019-0572-3
work_keys_str_mv AT mezhenskayadaria m2ebaseduniversalinfluenzavaccinesahistoricaloverviewandnewapproachestodevelopment
AT isakovasivakirina m2ebaseduniversalinfluenzavaccinesahistoricaloverviewandnewapproachestodevelopment
AT rudenkolarisa m2ebaseduniversalinfluenzavaccinesahistoricaloverviewandnewapproachestodevelopment